MiNK Therapeutics to Host R&D Event November 10, 2022
- Experts in disease pathways discuss clinical data of allo-iNKTs
- R&D strategy driving pipeline momentum, productivity, and innovation
- Internal scalable manufacturing of fully allogeneic iNKT cells; expanded capacity to ~700,000 doses
- R&D event:
November 10th from 4:00-6:00 pm ET, Boston, MA, and webcast
The R&D event will focus on the Company’s novel iNKT cell therapy platform and highlight its five presentations at the
The program will feature leaders in immuno-oncology and cell therapy, including members of the Company’s management team and external thought leaders including:
Terese Hammond, M.D., Associate Program Medical Director, Providence Saint John’s Health Center; Director, SCoRE ( Sound Center of Research Excellence). Lydia Lynch, Ph.D., Associate Professor of Medicine, Brigham and Women's Hospital, Harvard Medical School. Manuel Hidalgo, M.D, Ph.D., Chief of the Division of Hematology and Medical Oncologyat Weill Cornell Department of Medicine. David Einstein, M.D., Genitourinary Oncologist, Beth Israel Deaconess Medical Center; Assistant Professor, Harvard Medical School.
The event will be webcasted live and institutional investors and analysts are invited to attend in person. Individuals interested in attending the event in person should contact MiNK Therapeutics Investor Relations at firstname.lastname@example.org. The live webcast will be available on the Events & Presentations page of the Company’s website at https://investor.minktherapeutics.com/events-and-presentations. To register for the webcast, please click here. Following the webcast an archived version will be available on the MiNK website.
Source: MiNK Therapeutics